Compared with the control group, the levels of cardiac hypertrophy markers including atrial natriuretic peptide (ANP), brain/B‐type natriuretic peptide (BNP) and β‐myosin heavy chain (β‐MHC) increased significantly (p < 0.05) in CB‐GLP‐1 group, while ANP and BNP decreased markedly after GLP‐1 treatment, β‐MHC levels (p < 0.05) (Figure 3B–E). This evidence concerns the gene GLP1R and cardiac hypertrophy.